ADARx Pharmaceuticals Inc. Common Stock (ADRX) — AI-Powered Stock Analysis & Research

Analysis updated Sep 28, 2026 — scores and signals refreshed daily.

ADARx Pharmaceuticals Inc. Common Stock (ADRX) stock analysis — updated Sep 28, 2026: Q-Score 50/100 — Unrated. AI alpha score, Graham intrinsic value, ML forecast, technicals and insider activity.

Key Quantitative Facts

At-a-Glance Metrics

• Sector: Health Care
• Q-Score Verdict: Unrated (50.0)

Current Q-Score verdict: Unrated (50.0).

How This Analysis Is Built

StoQuant's analysis of ADARx Pharmaceuticals Inc. Common Stock (ADRX) is refreshed every trading day. The Q-Score combines discounted cash flow valuation, earnings quality, competitive moat, analyst consensus, ML return forecasts, technical momentum and market sentiment into a single 0–100 composite. Insider transactions from SEC Form 4 filings, the Graham intrinsic value estimate and signal coverage are recomputed as new data arrives, so this page always reflects the latest available information.

Recent Price Action & History

Trading Data & Technical Analysis

ADRX stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.

Date	High	Low	Close
2026-09-25	$23.21	$19.00	$19.35
2026-09-28	$21.77	$18.50	$20.09

Peer Comparison in Health Care

Sector Peers & Valuation Comparison

How ADARx Pharmaceuticals Inc. Common Stock stacks up against same-sector peers on market capitalization and alpha scores:

Ticker	Company	Market Cap	Alpha Score
AZN	AstraZeneca PLC	$290.7B	—
NVS	Novartis AG	$287.1B	—
NVO	Novo Nordisk A/S	$200.3B	—
SNY	Sanofi	$107.6B	—
GSK	GSK plc	$102.1B	—

Explore Sector Analysis

View all Health Care stocks by valuation and signals →

Key Analysis Points for ADARx Pharmaceuticals Inc. Common Stock

What Drove ADRX's Score

ADARx Pharmaceuticals Inc. Common Stock (ADRX) does not yet have a scored dimension breakdown. The composite verdict is Unrated (50.0). See Q-Score methodology for how these dimensions are weighted and combined.

What StoQuant Measures for ADRX

Core Signals & Metrics

• AI Alpha (Gem) Score: Combines 15+ technical signals (momentum, RSI, moving averages) with fundamentals (earnings surprise, growth consistency) and sentiment. 0–100 scale, residualized by sector so peer-relative strength is visible.
• Benjamin Graham Intrinsic Value: DCF-based valuation using conservative earnings assumptions and sector-median discount rates. Margin of safety measures distance from intrinsic value to current price.
• Composite Q-Score: Blends DCF upside potential, earnings quality (Piotroski F-Score, Altman Z-Score for distress risk), competitive moat score, analyst consensus, and social/news sentiment into one 0–100 verdict.
• ML Price Forecasts: Probability estimates using historical price/volume patterns.
• Insider & Institutional Flow: Officer and large shareholder transactions from SEC filings (10-K, Form 4), concentration analysis, and transaction patterns over 14/90-day windows. See insider activity methodology.
• Sector & Macro Context: Market regime classification (bull/bear/correction), sector rotation, and portfolio context. Same stock signal reads differently across market environments.

Learn StoQuant's Signals & Scoring

Knowledge Base & Methodology

All StoQuant signals are explained in our knowledge base:

• Q-Score Methodology — How StoQuant combines dimensions: DCF, earnings quality, moat, analyst consensus, ML, sentiment
• Portfolio Construction — Building balanced portfolios with StoQuant signals
• Diversification & Correlation — Cross-sector allocation and risk-adjusted returns

Compare & Research Tools

Direct Comparisons

• ADRX vs AZN — comparison
• ADRX vs NVS — comparison
• ADRX vs NVO — comparison
• ADRX vs SNY — comparison
• ADRX vs GSK — comparison
• ADRX vs TAK — comparison
• ADRX vs ARGX — comparison
• ADRX vs HLN — comparison
• ADRX vs TEVA — comparison
• ADRX vs ONC — comparison
• ADRX vs ALC — comparison
• ADRX vs PHG — comparison

Broader Research Tools

• Stock Screener — Filter 3,600+ stocks by Q-Score, alpha, Graham value, insider flow
• ML Stock Forecast — Return probability forecast with confidence intervals and driver analysis
• Full Stock Screener — Filter 3,600+ tickers by metrics, find outliers in any category

Sector-Specific Research

Health Care Hub — Top performers and valuation outliers in Health Care

Free Daily Digest: ADRX in Your Inbox

Curated Signals for Your Watchlist

Get daily updates on ADARx Pharmaceuticals Inc. Common Stock (ADRX): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.

Subscribe Now

Subscribe

See a sample digest • Unsubscribe anytime • Privacy policy

About StoQuant

Platform Overview

StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.

Embed & Share

Share ADRX Q-Score Badge

Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:

<a href="https://stoquant.com/research/ADRX"><img src="https://stoquant.com/badge/ADRX.svg" alt="ADARx Pharmaceuticals Inc. Common Stock (ADRX) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>

Disclaimer & Methodology

How StoQuant Works

StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.

Learn More

Full methodology • Terms of use • Contact us.

Get the StoQuant digest — free

Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.

Subscribe free